DK1250926T3 - Anvendelse af vanduoplöseligt S-camptothecin med en lukket lactonring i fremstilling af et medikament til behandling af coloncancer - Google Patents

Anvendelse af vanduoplöseligt S-camptothecin med en lukket lactonring i fremstilling af et medikament til behandling af coloncancer

Info

Publication number: DK1250926T3
Authority: DK; Denmark
Prior art keywords: camptothecin; treatment; insoluble; water; colon cancer
Prior art date: 1993-01-15

Application number

DK02015200T

Other languages

English (en)

Inventor

Beppino C Giovanella

Hellmuth R Hinz

Anthony J Kozielski

John S Stehlin

Original Assignee

Stehlin Foundation For Cancer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-01-15

Filing date

1994-01-14

Publication date

2008-07-07

1994-01-14 Application filed by Stehlin Foundation For Cancer filed Critical Stehlin Foundation For Cancer

2008-07-07 Application granted granted Critical

2008-07-07 Publication of DK1250926T3 publication Critical patent/DK1250926T3/da

Links

239000003814 drug Substances 0.000 title abstract 3
206010009944 Colon cancer Diseases 0.000 title abstract 2
229940127093 camptothecin Drugs 0.000 title abstract 2
208000029742 colonic neoplasm Diseases 0.000 title abstract 2
150000002596 lactones Chemical group 0.000 title abstract 2
229940079593 drug Drugs 0.000 title 1
FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 abstract 2
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract 2
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 1
238000007918 intramuscular administration Methods 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK02015200T 1993-01-15 1994-01-14 Anvendelse af vanduoplöseligt S-camptothecin med en lukket lactonring i fremstilling af et medikament til behandling af coloncancer DK1250926T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US284493A	1993-01-15	1993-01-15
PCT/US1994/000403 WO1994015604A1 (en)	1993-01-15	1994-01-14	Transdermal treatment of cancer with water-insoluble s-camptothecin of the closed lactone ring form

Publications (1)

Publication Number	Publication Date
DK1250926T3 true DK1250926T3 (da)	2008-07-07

Family

ID=21702794

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK94907804T DK0678025T3 (da)	1993-01-15	1994-01-14	Transdermal behandling af cancer med vand-ouopløslig S-camptothecin af den lukkede lactonringform
DK97101631T DK0778024T3 (da)	1993-01-15	1994-01-14	Oral eller intramuskulær behandling af pancreascancer med vanduopløselig S-camptothecin i lukket lactonring-formen
DK02015200T DK1250926T3 (da)	1993-01-15	1994-01-14	Anvendelse af vanduoplöseligt S-camptothecin med en lukket lactonring i fremstilling af et medikament til behandling af coloncancer

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DK94907804T DK0678025T3 (da)	1993-01-15	1994-01-14	Transdermal behandling af cancer med vand-ouopløslig S-camptothecin af den lukkede lactonringform
DK97101631T DK0778024T3 (da)	1993-01-15	1994-01-14	Oral eller intramuskulær behandling af pancreascancer med vanduopløselig S-camptothecin i lukket lactonring-formen

Country Status (9)

Country	Link
EP (3)	EP0678025B1 (da)
JP (1)	JP3099128B2 (da)
AT (3)	ATE165003T1 (da)
CA (1)	CA2148822C (da)
DE (3)	DE69431731T2 (da)
DK (3)	DK0678025T3 (da)
ES (3)	ES2301590T3 (da)
PT (1)	PT1250926E (da)
WO (1)	WO1994015604A1 (da)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5244903A (en) *	1987-03-31	1993-09-14	Research Triangle Institute	Camptothecin analogs as potent inhibitors of topoisomerase I
DK0418099T3 (da) *	1989-09-15	2002-04-02	Res Triangle Inst	Fremgangsmåde til fremstilling af 10,11-methylendioxy-20(RS)-camptothecin og 10,11-methylendioxy-20(S)-camptothecinanaloger
US5422344A (en) *	1990-05-08	1995-06-06	The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services	Method of treating retroviral infections in mammals
ATE136898T1 (de) *	1991-10-29	1996-05-15	Glaxo Wellcome Inc	Wasserlösliche camptothecinderivate
WO1993009782A1 (en) *	1991-11-15	1993-05-27	Smithkline Beecham Corporation	Combination chemotherapy
AU2394392A (en) *	1991-12-10	1993-07-19	Smithkline Beecham Corporation	Treatment of colorectal cancer

1994
- 1994-01-14 EP EP94907804A patent/EP0678025B1/en not_active Expired - Lifetime
- 1994-01-14 DK DK94907804T patent/DK0678025T3/da active
- 1994-01-14 EP EP02015200A patent/EP1250926B1/en not_active Expired - Lifetime
- 1994-01-14 DE DE69431731T patent/DE69431731T2/de not_active Expired - Fee Related
- 1994-01-14 CA CA002148822A patent/CA2148822C/en not_active Expired - Fee Related
- 1994-01-14 AT AT94907804T patent/ATE165003T1/de not_active IP Right Cessation
- 1994-01-14 WO PCT/US1994/000403 patent/WO1994015604A1/en not_active Ceased
- 1994-01-14 DK DK97101631T patent/DK0778024T3/da active
- 1994-01-14 JP JP06516305A patent/JP3099128B2/ja not_active Expired - Fee Related
- 1994-01-14 DE DE69435084T patent/DE69435084T2/de not_active Expired - Fee Related
- 1994-01-14 PT PT02015200T patent/PT1250926E/pt unknown
- 1994-01-14 DK DK02015200T patent/DK1250926T3/da active
- 1994-01-14 AT AT97101631T patent/ATE227573T1/de not_active IP Right Cessation
- 1994-01-14 ES ES02015200T patent/ES2301590T3/es not_active Expired - Lifetime
- 1994-01-14 DE DE69409633T patent/DE69409633T2/de not_active Expired - Fee Related
- 1994-01-14 EP EP97101631A patent/EP0778024B1/en not_active Expired - Lifetime
- 1994-01-14 AT AT02015200T patent/ATE388706T1/de not_active IP Right Cessation
- 1994-01-14 ES ES94907804T patent/ES2114681T3/es not_active Expired - Lifetime
- 1994-01-14 ES ES97101631T patent/ES2186812T3/es not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DK0778024T3 (da)	2002-12-23
EP0678025B1 (en)	1998-04-15
CA2148822A1 (en)	1994-07-21
EP0778024A1 (en)	1997-06-11
DE69409633T2 (de)	1998-08-06
DE69435084T2 (de)	2009-03-19
EP1250926A2 (en)	2002-10-23
ATE165003T1 (de)	1998-05-15
DK0678025T3 (da)	1998-10-07
EP0678025A1 (en)	1995-10-25
JP3099128B2 (ja)	2000-10-16
DE69409633D1 (de)	1998-05-20
EP0778024B1 (en)	2002-11-13
JPH08505626A (ja)	1996-06-18
ES2114681T3 (es)	1998-06-01
ATE388706T1 (de)	2008-03-15
EP1250926B1 (en)	2008-03-12
ES2301590T3 (es)	2008-07-01
DE69431731T2 (de)	2003-03-13
CA2148822C (en)	2001-03-27
ES2186812T3 (es)	2003-05-16
PT1250926E (pt)	2008-06-11
ATE227573T1 (de)	2002-11-15
WO1994015604A1 (en)	1994-07-21
DE69431731D1 (de)	2002-12-19
DE69435084D1 (de)	2008-04-24
EP1250926A3 (en)	2002-11-20

Publication	Publication Date	Title
DK203787A (da)	1987-10-24	Praeparat til nasal administrering
DK0449247T3 (da)	1994-11-21	Farmaceutisk formulering indeholdende galanthamin til behandling af alkoholisme
ATE352289T1 (de)	2007-02-15	Mittel zur oralen verabreichung
DK0831827T3 (da)	2007-09-10	Nye formuleringer til transdermal levering af pergolid
DE3779500D1 (de)	1992-07-09	Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
DK0668763T3 (da)	2002-06-03	Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
ATE247471T1 (de)	2003-09-15	Cisplatin und topotecan enthaltende zusammensetzung als antitumor.
EE04606B1 (et)	2006-04-17	H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
ATE151637T1 (de)	1997-05-15	Heterozyklische verbindungen
DK541189A (da)	1990-05-02	Anvendelse af nalmefen eller naltrexon til fremstilling af et laegemiddel til behandling af interstitiel cystitis
DK598288D0 (da)	1988-10-27	Vaeskeformig farmaceutisk sammensaetning til behandling af hoste og oemhed i halsen
DK0678025T3 (da)	1998-10-07	Transdermal behandling af cancer med vand-ouopløslig S-camptothecin af den lukkede lactonringform
GB9202993D0 (en)	1992-03-25	Novel pharmaceutical uses of bilobalide and derivatives thereof and pharmaceutical compositions adapted for such use
DE69233773D1 (de)	2009-11-19	Verwendung von topotecan zur herstellung eines medikaments zur verwendung in der behandlung von ovarialkrebs
DK0457336T3 (da)	1995-08-07	Ny anvendelse af 4-carbamoyl-1-beta-D-ribofuranosylimidazolium-5-olat
SE8107833L (sv)	1982-07-01	Substituerade tetrahydro-1,2,4-oxadiazin-5-on-derivat med kramplosande verkan, sett for deras framstellning och farmaceutiska beredningar innehallandedem
NO901231L (no)	1990-09-18	Fremgangsmaate for fremstilling av et farmasoeytisk preparat